JP2023536067A5 - - Google Patents

Info

Publication number
JP2023536067A5
JP2023536067A5 JP2023503171A JP2023503171A JP2023536067A5 JP 2023536067 A5 JP2023536067 A5 JP 2023536067A5 JP 2023503171 A JP2023503171 A JP 2023503171A JP 2023503171 A JP2023503171 A JP 2023503171A JP 2023536067 A5 JP2023536067 A5 JP 2023536067A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
expression cassette
vector
slc13a5
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/042930 external-priority patent/WO2022020697A1/en
Publication of JP2023536067A publication Critical patent/JP2023536067A/ja
Publication of JP2023536067A5 publication Critical patent/JP2023536067A5/ja
Pending legal-status Critical Current

Links

JP2023503171A 2020-07-23 2021-07-23 最適化されたslc13a5遺伝子および発現カセットならびにそれらの使用 Pending JP2023536067A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055795P 2020-07-23 2020-07-23
US63/055,795 2020-07-23
PCT/US2021/042930 WO2022020697A1 (en) 2020-07-23 2021-07-23 Optimized slc13a5 genes and expression cassettes and their use

Publications (2)

Publication Number Publication Date
JP2023536067A JP2023536067A (ja) 2023-08-23
JP2023536067A5 true JP2023536067A5 (cg-RX-API-DMAC7.html) 2024-07-09

Family

ID=79728993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503171A Pending JP2023536067A (ja) 2020-07-23 2021-07-23 最適化されたslc13a5遺伝子および発現カセットならびにそれらの使用

Country Status (6)

Country Link
US (1) US20230285595A1 (cg-RX-API-DMAC7.html)
EP (2) EP4700126A3 (cg-RX-API-DMAC7.html)
JP (1) JP2023536067A (cg-RX-API-DMAC7.html)
CA (1) CA3186207A1 (cg-RX-API-DMAC7.html)
ES (1) ES3057565T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022020697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240342314A1 (en) * 2021-09-30 2024-10-17 The Board Of Regents Of The University Of Texas System Slc13a5 gene therapy vectors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
AU774706B2 (en) 1998-09-22 2004-07-08 Johns Hopkins University, The Methods for large-scale production of recombinant AAV vectors
DE69936104T2 (de) 1998-11-05 2008-01-17 The Trustees Of The University Of Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
US7465583B2 (en) * 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US20050095240A1 (en) * 2002-11-22 2005-05-05 Medical College Of Georgia Research NaCT as a target for lifespan expansion and weight reduction
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
PL2900686T3 (pl) 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
AU2015349759B2 (en) 2014-11-21 2022-01-06 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
WO2017180587A2 (en) * 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
JP2019517274A (ja) * 2016-06-13 2019-06-24 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill 最適化されたcln1遺伝子および発現カセットおよびそれらの使用
EP3692158A4 (en) * 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
US20240342314A1 (en) * 2021-09-30 2024-10-17 The Board Of Regents Of The University Of Texas System Slc13a5 gene therapy vectors and uses thereof

Similar Documents

Publication Publication Date Title
JP7374119B2 (ja) 減少した肝臓向性を有するAAV9とAAVrh74とのハイブリッド組換えアデノ随伴ウイルス血清型
JP7607007B2 (ja) 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
AU2017227803B2 (en) Therapy for frontotemporal dementia
KR102527259B1 (ko) 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
JP2022141670A5 (cg-RX-API-DMAC7.html)
RU2653444C2 (ru) Композиции вектора aav и способы переноса генов в клетки, органы и ткани
CN116096431A (zh) 肽修饰的aav衣壳
JP2021532812A5 (cg-RX-API-DMAC7.html)
JP2022500066A5 (cg-RX-API-DMAC7.html)
JP2021502060A5 (cg-RX-API-DMAC7.html)
JP2023514242A5 (cg-RX-API-DMAC7.html)
Miyake et al. Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors
TW201629225A (zh) 第九因子基因療法
IL262852B1 (en) Treatment of complement-mediated disorders
JP2022530824A5 (cg-RX-API-DMAC7.html)
JP2021533805A5 (cg-RX-API-DMAC7.html)
RU2018145010A (ru) Оптимизированные гены и экспрессионные кассеты cln1, и их применение
US11891616B2 (en) Transgene cassettes designed to express a human MECP2 gene
JP2023537980A5 (cg-RX-API-DMAC7.html)
JP7691367B2 (ja) Cln3ポリヌクレオチドのアデノ随伴ウイルス送達
JP2025513066A5 (cg-RX-API-DMAC7.html)
JP2021533801A5 (cg-RX-API-DMAC7.html)
CN113574176A (zh) 腺相关病毒对cln6多核苷酸的递送
CA3178591A1 (en) Immunosuppressive agents and viral delivery re-dosing methods for gene therapy
JP2022530264A5 (cg-RX-API-DMAC7.html)